7.4.4.2. treatment patients non-clear-cell metastatic rcc (general considerations). sake historical purposes, panel recognises use non-cc-mrcc possible refer distinct subtype. heterogenous group including papillary, chromophobe rare tumours widely differing tumour biology. patients non-cc-mrcc therefore referred clinical trial, appropriate.while phase iii trials patients non-cc-mrcc reported increasingly recognised study specific subtypes higher incidence non-ccrcc. papillary rcc (prcc) comprise majority tumours defined non-ccrcc, evidence available subtype, either trials specifically selecting prcc included high percentage. 7.4.4.2.1. treatment patients papillary metastatic rcc small single-arm trials sunitinib everolimus [593-597]. agents widely given prcc, recent data suggests cabozantinib combinations may preferable . prcc new evidence available swog papmet randomised phase ii trial compared sunitinib cabozantinib, crizotinib savolitinib 152 patients papillary mrcc . progression- free survival longer patients cabozantinib group (median 9.0 months, 95% ci: 6-12) sunitinib group (5.6 months, ci: 3-7; hr progression death 0.60 [0.37-0.97, one-sided p = 0.019]). response rate cabozantinib 23% vs. 4% sunitinib (two-sided p = 0.010). savolitinib crizotinib improve pfs compared sunitinib. grade iii iv adverse events occurred 69% (31/45) patients receiving sunitinib, 74% (32/43) patients receiving cabozantinib, 37% (10/27) receiving crizotinib, 39% (11/28) receiving savolitinib; one grade v thromboembolic event recorded cabozantinib group. results support adding cabozantinib option patients papillary mrcc based superior pfs results compared sunitinib. addition, savolitinib investigated savoir trial first-line treatment met-driven tumours defined chromosome 7 gain, met amplification, met kinase domain variations hepatocyte growth factor amplification dna alteration analysis (~30% screened patients met positive). limited patient group, savolitinib (n = 27) compared sunitinib (n = 33). trial stopped early, largely due poor accrual. efficacy data appeared favour savolitinib (median pfs 7.0 months, 95% ci: 2.8 months-nr vs. 5.6 months, 95% ci: 4.1-6.9 months, pfs hr: 0.71, 95% ci: 0.37-1.36, os hr: 0.51,94% ci: 0.21-1.17, rr: 27% vs. 7%, savolitinib sunitinib, respectively). median os savolitinib reported, savolitinib better tolerated compared sunitinib 42% grade > 3 aes compared 81% sunitinib. ongoing trials confirm findings. results trials required recommendations made. evidence tki + io based combination derived two phase ii studies lenvatinib plus pembrolizumab cabozantinib nivolumab. keynote-b61 phase ii trial investigated lenvatinib plus pembrolizumab administered non-ccrcc patients 93 patients (59%) prcc . primary endpoint objective response 54% prcc patients, median follow-up 14.9 months, providing evidence good efficacy tki + io based combinations. cabozantinib nivolumab study enrolled 40 patients papillary unclassified rcc response rate 47% pfs 13 (7-16) months . trial chromophobe rcc excluded percentage prcc 68%. indirect comparisons suggest data compare increased efficacy vegfr-tki monotherapy alone. efficacy pembrolizumab prcc subset (118/165) was; rr: 29%, pfs: 5.5 months (95% ci: 3.9-6.1 months) os: 31.5 months (95% ci: 25.5 months-nr), results based single-arm phase ii study . pembrolizumab considered setting due high unmet need; although vegfr tki + io combination may preferable. 7.4.4.2.2. summary evidence recommendations systemic therapy papillary metastatic rcc summary evidencelecabozantinib improved pfs sunitinib patients advanced prcc without additional molecular testing.2alenvatinib plus pembrolizumab cabozantinib plus nivolumab demonstrated response rates 47-54% median pfs rates >12 months2apembrolizumab resulted long-term median os single-arm study prcc subgroup.2a recommendationsstrength ratingoffer cabozantinib patients papillary rcc (prcc) based positive randomised controlled trial.weakoffer lenvatinib plus pembrolizumab nivolumab plus cabozantinib patients prcc based small single-arm trials.weak 7.4.4.2.3. treatment patients metastatic non-ccrcc papillary rcc evidence surrounding systemic therapy non-ccrcc tumours prcc especially weak relied subset analysis randomised phase ii trials well expanded access programmes. results consistently demonstrate outcome patients targeted therapy poorer ccrcc. treatment non-cc-mrcc focused temsirolimus, everolimus, sorafenib, sunitinib, cabozantinib pembrolizumab past [593,602,604-606]. recent data single-arm phase ii trials lenvatinib plus pembrolizumab demonstrated clinical efficacy io+tki combinations different non-ccrcc subgroups. . meadian orr across different non-ccrcc subgroups 158 patiens 49%, 12 months pfs os rates 63% 82%. 7.4.4.2.4. summary evidence recommendation systemic therapy chromophobe unclassified rcc summary evidenceleboth mtor inhibitors vegf-targeted therapies limited activity non-cc-mrcc. non-significant trend improved oncological outcomes sunitinib everolimus cabozantinib sunitinib.2ain non-cc-mrcc, sunitinib improved pfs everolimus sr phase ii trials subgroups patients.1ain non—cc-mrcc lenvatinib plus pemrolizumab demonstrated clinical efficacy different non-ccrcc subgroups2ain non—cc-mrcc cabozantinib plus nivolumab demonstrated clinical efficacy different non-ccrcc subgroups except chromophobe rcc excluded study2a recommendationsstrength ratingoffer sunitinib patients non-clear cell renal cell carcinoma (cc-rcc) subtypes papillary rcc.weakoffer lenvatinib plus pembrolizumab patients non-ccrcc subtypes.weakoffer cabozantinib nivolumab patients non-ccrcc subtypes chromophobe rcc.weak